VIPAR, known for its role in vesicle trafficking and apical-basolateral polarity regulation, is influenced by a variety of compounds that modulate cellular signaling pathways. Certain activators target the adenylyl cyclase-cAMP axis to elevate intracellular cAMP levels, thereby potentially augmenting the vesicular trafficking processes in which VIPAR partakes. Additionally, the function of VIPAR in vesicular transport can be enhanced by phospholipids that regulate membrane trafficking. When the epidermal growth factor interacts with its receptor, it initiates a cascade of endocytosis and recycling pathways, which could involve VIPAR in the intricate endosomal sorting mechanisms. There are also compounds that maintain elevated cAMP levels by inhibiting phosphodiesterases, sustaining the indirect support of VIPAR's associated signaling.
Furthermore, the use of nonhydrolyzable GTP analogs implicates the activation of GTPases that are instrumental in vesicle formation, potentially enhancing VIPAR's function in these processes. The availability of coenzymes for redox reactions is crucial for cellular metabolism, which in turn may support the vesicle turnover where VIPAR is involved. Disruption of the Golgi structure or alterations in intracellular pH through various agents can lead to a redistribution of proteins, including VIPAR, to different cellular compartments, thereby influencing its activity. Inhibition of specific enzymes and pathways that regulate endocytosis and vesicle trafficking can result in a compensatory upregulation of alternative pathways, in which VIPAR could be a key player, ensuring the maintenance of cellular homeostasis and proper protein sorting.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $260.00 $350.00 $500.00 | 34 | |
Phosphodiesterase inhibitor that prevents cAMP breakdown, indirectly sustaining VIPAR activity related to cAMP signaling. | ||||||
Guanosine 5′-O-(3-thiotriphosphate) tetralithium salt | 94825-44-2 | sc-202639 | 10 mg | $465.00 | ||
A nonhydrolyzable GTP analog that can activate GTPases involved in vesicle formation, potentially enhancing VIPAR function. | ||||||
NAD+, Free Acid | 53-84-9 | sc-208084B sc-208084 sc-208084A sc-208084C sc-208084D sc-208084E sc-208084F | 1 g 5 g 10 g 25 g 100 g 1 kg 5 kg | $57.00 $191.00 $302.00 $450.00 $1800.00 $3570.00 $10710.00 | 4 | |
Coenzyme in redox reactions, may indirectly support VIPAR function by maintaining cellular metabolism and vesicle turnover. | ||||||
Brefeldin A | 20350-15-6 | sc-200861C sc-200861 sc-200861A sc-200861B | 1 mg 5 mg 25 mg 100 mg | $31.00 $53.00 $124.00 $374.00 | 25 | |
Disrupts Golgi structure and function, which can lead to redistribution of proteins like VIPAR to endosomal compartments. | ||||||
Monensin A | 17090-79-8 | sc-362032 sc-362032A | 5 mg 25 mg | $155.00 $525.00 | ||
Ionophore that alters intracellular pH and could enhance VIPAR-mediated trafficking by affecting the endosomal system. | ||||||
Chlorpromazine | 50-53-3 | sc-357313 sc-357313A | 5 g 25 g | $61.00 $110.00 | 21 | |
Blocks clathrin-mediated endocytosis which may indirectly increase VIPAR activity by altering endosomal pathway dynamics. | ||||||
Genistein | 446-72-0 | sc-3515 sc-3515A sc-3515B sc-3515C sc-3515D sc-3515E sc-3515F | 100 mg 500 mg 1 g 5 g 10 g 25 g 100 g | $45.00 $164.00 $200.00 $402.00 $575.00 $981.00 $2031.00 | 46 | |
Tyrosine kinase inhibitor which can modulate endocytosis and trafficking pathways, potentially affecting VIPAR function. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
PI3 kinase inhibitor that alters vesicle trafficking and may indirectly enhance the vesicular role of VIPAR. | ||||||
Dynamin Inhibitor I, Dynasore | 304448-55-3 | sc-202592 | 10 mg | $89.00 | 44 | |
GTPase inhibitor which impairs dynamin-mediated endocytosis, potentially compensating through VIPAR-mediated pathways. | ||||||